Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/1/1999


1.		Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral TMX vs Weekly Intravenous 5-FU for Advanced Pancreatic Cancer (Summary Last Modified 01/99)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				21 and over				Pharmaceutical / Industry				ALFACELL-P30-300 NCI-V95-0752

Last Modified: 8/1/1998


2.		Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen vs Weekly Intravenous Gemcitabine for Advanced Pancreatic Cancer (Summary Last Modified 08/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and over				Pharmaceutical / Industry				ALFACELL-P30-303 NCI-V96-0938

Last Modified: 10/29/2007 First Published: 12/1/1997


3.		ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and over				Pharmaceutical / Industry				ALFACELL-P30-302 NCI-V97-1273, NCT00003034

Last Modified: 3/1/1998


4.		Phase II Pilot Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen for Prostate Cancer Patients with an Elevated PSA After Failing Local Therapy (Summary Last Modified 03/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Pharmaceutical / Industry				ALFACELL-P30-400 NCI-V96-0937

Last Modified: 6/1/1997


5.		Phase II Study of P-30 Protein Administered as a Single Weekly Intravenous Bolus Dose in Advanced Malignant Mesothelioma (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				21 and over				Other				TCSC-P-30-P/PHII NCI-V92-0008

Last Modified: 2/1/1991


6.		Phase I Study of P-30 Protein Administered by Weekly Intravenous Bolus Injections in Patients with Cancer (Summary Last Modified 02/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				21 and over								TCSC-P-30-PROTEIN NCI-V90-0188

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute